These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 21521022)
41. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. Timmerman P; Herling C; Stoellner D; Jaitner B; Pihl S; Elsby K; Henderson N; Barroso B; Fischmann S; Companjen A; Versteilen A; Bates S; Kingsley C; Kunz U; Bioanalysis; 2012 Aug; 4(15):1883-94. PubMed ID: 22943619 [TBL] [Abstract][Full Text] [Related]
42. Fit-for-purpose biomarker method validation in anticancer drug development. Cummings J; Ward TH; Dive C Drug Discov Today; 2010 Oct; 15(19-20):816-25. PubMed ID: 20708097 [TBL] [Abstract][Full Text] [Related]
43. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations. Ogungbenro K; Aarons L J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118 [TBL] [Abstract][Full Text] [Related]
44. Multicity study of air pollution and mortality in Latin America (the ESCALA study). Romieu I; Gouveia N; Cifuentes LA; de Leon AP; Junger W; Vera J; Strappa V; Hurtado-Díaz M; Miranda-Soberanis V; Rojas-Bracho L; Carbajal-Arroyo L; Tzintzun-Cervantes G; Res Rep Health Eff Inst; 2012 Oct; (171):5-86. PubMed ID: 23311234 [TBL] [Abstract][Full Text] [Related]
45. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Becquemont L Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963 [TBL] [Abstract][Full Text] [Related]
46. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies. Hosmane B; Locke C; Chiu YL J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591 [TBL] [Abstract][Full Text] [Related]
47. How large a training set is needed to develop a classifier for microarray data? Dobbin KK; Zhao Y; Simon RM Clin Cancer Res; 2008 Jan; 14(1):108-14. PubMed ID: 18172259 [TBL] [Abstract][Full Text] [Related]
48. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Molokhia M; McKeigue P Pharmacogenomics; 2006 Jun; 7(4):633-8. PubMed ID: 16753010 [TBL] [Abstract][Full Text] [Related]
49. Sample size consideration for immunoassay screening cut-point determination. Zhang J; Zhang L; Yang H J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778 [TBL] [Abstract][Full Text] [Related]
50. Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update. Rolan P; Danhof M; Stanski D; Peck C Eur J Pharm Sci; 2007 Feb; 30(2):107-12. PubMed ID: 17196378 [TBL] [Abstract][Full Text] [Related]
51. Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky? Avigan MI Per Med; 2009 Jan; 6(1):67-78. PubMed ID: 29783386 [TBL] [Abstract][Full Text] [Related]
52. [HLA and susceptibility to adverse drug reactions]. Mizuki N Nippon Ganka Gakkai Zasshi; 2012 Jun; 116(6):543-5. PubMed ID: 22774592 [No Abstract] [Full Text] [Related]